Methodology by which to identify candidate PARP inhibitors with strong anti-cancer properties (i.e. “trapping” compounds), as well as PARP inhibitors with low cellular toxicity for treatment of stroke, diabetes, myocardial infarction, neurodegenerative diseases and other diseases (i.e. a “non-trapping” compounds)
Published: 10/30/2023